• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JCI Insight . Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus

tetano

Editor, Senior Moderator
JCI Insight


. 2024 Mar 8;9(5):e176556.
doi: 10.1172/jci.insight.176556. Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus

Kavita Y Sarin[SUP] 1 [/SUP], Hong Zheng[SUP] 2 3 [/SUP], Yashaar Chaichian[SUP] 4 [/SUP], Prabhu S Arunachalam[SUP] 2 5 [/SUP], Gayathri Swaminathan[SUP] 1 [/SUP], Alec Eschholz[SUP] 1 [/SUP], Fei Gao[SUP] 2 [/SUP], Oliver F Wirz[SUP] 6 [/SUP], Brandon Lam[SUP] 6 [/SUP], Emily Yang[SUP] 4 [/SUP], Lori W Lee[SUP] 7 [/SUP], Allan Feng[SUP] 4 [/SUP], Matthew A Lewis[SUP] 1 [/SUP], Janice Lin[SUP] 4 [/SUP], Holden T Maecker[SUP] 2 [/SUP], Scott D Boyd[SUP] 6 [/SUP], Mark M Davis[SUP] 2 8 [/SUP], Kari C Nadeau[SUP] 2 9 [/SUP], Bali Pulendran[SUP] 6 10 [/SUP], Purvesh Khatri[SUP] 2 3 [/SUP], Paul J Utz[SUP] 2 4 [/SUP], Lisa C Zaba[SUP] 1 [/SUP]



Affiliations
Free article Abstract

Understanding the immune responses to SARS-CoV-2 vaccination is critical to optimizing vaccination strategies for individuals with autoimmune diseases, such as systemic lupus erythematosus (SLE). Here, we comprehensively analyzed innate and adaptive immune responses in 19 patients with SLE receiving a complete 2-dose Pfizer-BioNTech mRNA vaccine (BNT162b2) regimen compared with a control cohort of 56 healthy control (HC) volunteers. Patients with SLE exhibited impaired neutralizing antibody production and antigen-specific CD4+ and CD8+ T cell responses relative to HC. Interestingly, antibody responses were only altered in patients with SLE treated with immunosuppressive therapies, whereas impairment of antigen-specific CD4+ and CD8+ T cell numbers was independent of medication. Patients with SLE also displayed reduced levels of circulating CXC motif chemokine ligands, CXCL9, CXCL10, CXCL11, and IFN-γ after secondary vaccination as well as downregulation of gene expression pathways indicative of compromised innate immune responses. Single-cell RNA-Seq analysis reveals that patients with SLE showed reduced levels of a vaccine-inducible monocyte population characterized by overexpression of IFN-response transcription factors. Thus, although 2 doses of BNT162b2 induced relatively robust immune responses in patients with SLE, our data demonstrate impairment of both innate and adaptive immune responses relative to HC, highlighting a need for population-specific vaccination studies.

Keywords: Adaptive immunity; Autoimmunity; Innate immunity; Vaccines.

 
Back
Top Bottom